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Abstract
Background: Systemic therapy for cancer metastatic lesions is difficult and generally renders a poor clinical
response. Structural analogs of cisplatin, the most widely used synthetic metal complexes, show toxic side-effects
and tumor cell resistance. Recently, palladium complexes with increased stability are being investigated to
circumvent these limitations, and a biphosphinic cyclopalladated complex {Pd2 [S(-)C
2, N-dmpa]2 (μ-dppe)Cl2}
named C7a efficiently controls the subcutaneous development of B16F10-Nex2 murine melanoma in syngeneic
mice. Presently, we investigated the melanoma cell killing mechanism induced by C7a, and extended preclinical
studies.
Methods: B16F10-Nex2 cells were treated in vitro with C7a in the presence/absence of DTT, and several
parameters related to apoptosis induction were evaluated. Preclinical studies were performed, and mice were
endovenously inoculated with B16F10-Nex2 cells, intraperitoneally treated with C7a, and lung metastatic nodules
were counted. The cytotoxic effects and the respiratory metabolism were also determined in human tumor cell
lines treated in vitro with C7a.
Results: Cyclopalladated complex interacts with thiol groups on the mitochondrial membrane proteins, causes
dissipation of the mitochondrial membrane potential, and induces Bax translocation from the cytosol to
mitochondria, colocalizing with a mitochondrial tracker. C7a also induced an increase in cytosolic calcium
concentration, mainly from intracellular compartments, and a significant decrease in the ATP levels. Activation of
effector caspases, chromatin condensation and DNA degradation, suggested that C7a activates the apoptotic
intrinsic pathway in murine melanoma cells. In the preclinical studies, the C7a complex protected against murine
metastatic melanoma and induced death in several human tumor cell lineages in vitro, including cisplatin-resistant
ones. The mitochondria-dependent cell death was also induced by C7a in human tumor cells.
Conclusions: The cyclopalladated C7a complex is an effective chemotherapeutic anticancer compound against
primary and metastatic murine and human tumors, including cisplatin-resistant cells, inducing apoptotic cell death
via the intrinsic pathway.
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The incidence of malignant melanoma is rising and has
not been associated with significantly better therapeutic
options. Treatments of choice for the systemic therapy
of metastatic lesions have used mono-chemo and immu-
notherapy, both with low records of clinical response.
Even the combination of several chemotherapeutic com-
pounds and the use of biochemotherapy protocols were
not able to improve the overall survival of patients
[reviewed in [1] and [2]]. In consequence, research
directed to the discovery of new antitumor compounds
is strongly stimulated.
Most synthetic metal complexes used as antitumor
chemotherapeutic compounds are structural analogs of
cisplatin. These compounds are frequently associated
with severe neuro/nephrotoxicity, myelosuppression side
effects, and tumor cell resistance [reviewed in [3]].
Although new analogs designed to circumvent toxic
side-effects were not as successful as expected, the
research on platinum complexes moved to areas of can-
cer-specific targeting, drug administration and drug
delivery [3]. Recently, new structural types of metallic
complexes aiming at increased antitumor efficiency, but
also at decreased toxicity in normal cells have been
introduced. Simultaneously, new targets in tumor cells
that could overcome resistance mechanisms have been
discovered. Palladium complexes are among these newly
described coordination compounds.
The first palladium complexes had little or no applica-
tion as antitumor compounds due to poor stability and
fast hydrolysis in biological environments. The use of
chelating ligands in the synthesis of palladium com-
plexes increased the stability of these compounds [[4],
reviewed in [5]].
Recently, palladium complexes have been tested as
antimicrobial and antitumor compounds. For example,
palladium (II) complexes containing isonicotinamide [6],
chiral b-aminoalcohol palladium complexes [7] and pal-
ladium(II) oxalate complexes [8] were cytotoxic to
human tumor cells in vitro,a tμM concentrations, but
the in vivo activity of these compounds in experimental
models have not been investigated.
During these studies it was established that the stability
of Pd complexes was further improved by the generation
of cyclopalladated compounds using cyclometallation
reactions [reviewed in [5]]. In addition to the increased
stability, cyclopalladated complexes were less toxic, mak-
ing them promising new antitumor compounds [[9-12],
reviewed in [5]].
A biphosphinic palladacycle complex [Pd(C
2,N - ( S (-)
dmpa)(dppf)] Cl induced apoptotic cell death in human
leukemia cells (HL-60 and Jurkat) by rupture of lysosomal
membrane and release of cathepsin B in the cytoplasm.
The IC50 dose after 5 h was 8 μM, and normal human
lymphocytes were not sensitive to the complex [13].
Another group of biphosphinic cyclopalladated com-
pounds, obtained from the cyclometallation agents N,
N-dimethyl-1-phenethyl-amine (dmpa), phenyl-2-pyridi-
nyl-acetylene or 1-phenyl-3-N, N-dimethylamine-pro-
pyne and containing the biphosphinic ligand 1,
ethanebis (diphenyl-phosphine) (dppe), were synthesized
and tested in vitro and in vivo in syngeneic murine mel-
anoma B16F10-Nex2 cells [14]. In this study with 7
cyclopalladated compounds, 3 complexes inhibited the
in vitro growth of murine melanoma cells at doses
lower than 1.25 μM, and one complex, named C7a, was
the most active in vivo, delaying subcutaneous tumor
growth and increasing animal survival. Cyclopalladated
C7a strongly affected the respiratory metabolism of
B16F10-Nex2 cells causing a collapse in the mitochon-
drial proton gradient, suggesting a possible effect on
mitochondria, and possibly leading cells to apoptosis,
since it was observed DNA degradation [14]. The addi-
tive anti-tumor protective effect of the C7a complex in
a gene therapy protocol with plasmids encoding IL-12
and an Fc-chimera of the soluble alpha chain of IL-13
receptor was demonstrated by Hebeler-Barbosa et al.
[15]. The combined therapy rendered a significant
reduction in the subcutaneous tumor evolution with
30% tumor-free mice.
It remained to be determined whether human tumor
cells or the metastatic experimental model of B16F10-
Nex2 cells were sensitive to this new compound and the
basis of the antitumor effect, thus validating the C7a
complex as a good candidate for clinical trials.
In the present work, we analyzed the mechanism of
action of the C7a complex on melanoma cells, deter-
mined the in vivo effect of cyclopalladated C7a on a pre-
clinical model of metastatic melanoma and the
cytotoxicity in vitro of the complex on several human
tumor cell lines, including some cisplatin-resistant
lineages.
Methods
Tumor cells and culture conditions
Murine B16F10-Nex2 melanoma cells were cloned at
the Experimental Oncology Unit, Federal University of
São Paulo, UNIFESP, as described elsewhere [16].
Human melanoma cell line SKmel25 was obtained from
the Memorial Sloan Kettering Cancer Center, New
York, and all other human cell lines were obtained from
the Ludwig Institute for Cancer Research (São Paulo).
Tumor cells were cultivated in complete RPMI-1640
medium, pH 7.2, supplemented with 10 mM N-2-hydro-
xyethylpiperazine-N’-2-ethanesulphonic acid (HEPES),
24 mM sodium bicarbonate, 40 mg/ml gentamycin, 100
Serrano et al. BMC Cancer 2011, 11:296
http://www.biomedcentral.com/1471-2407/11/296
Page 2 of 16U/mL penicillin, 100 μg/ml streptomycin and 10% fetal
calf serum (FCS), all from Invitrogen (CA, USA). Cells
were maintained in culture flasks at 37°C in humidified
atmosphere with 5% CO2, and were collected using
PBS-EDTA (1 mM) solution.
Animals
C57Bl/6 male mice (8 weeks old) were purchased from
CEDEME (Centro de Desenvolvimento de Modelos
Experimentais, UNIFESP), and maintained in sterilized
environment, with food and water ad libitum,i n1 2h
cycles of light/dark. All animal experiments were
approved by the Animal Experimentation Ethics Com-
mittee of UNIFESP, under protocol No. 1507/09.
Cyclopalladated compound
The cyclopalladated complex C7a was synthesized from
N, N-dimethyl-1-phenethylamide (dmpa), complexed to
1, 2 ethanebis (diphenylphosphine, dppe) ligant, as pre-
viously described in Rodrigues et al. [14] and its chemi-
cal formula is shown in Figure 1. The compound is
diluted to a final concentration of 10 mM in DMSO
(cell culture tested, Sigma Aldrich), and for in vivo and
in vitro assays diluted to the final concentration in com-
plete RPMI-1640 medium.
In vitro Cell Viability Assay
Tumor cells were seeded at 10
4 cells/well into 96 well-
plates (Corning Costar Co,N Y ,U S A ) ,a n d1 2hl a t e r ,
they were incubated with serially diluted C7a to a final
volume of 200 μL in complete RPMI medium. After 24
h incubation with C7a, the cytotoxic activity was deter-
mined by measuring cell viability by two different meth-
ods, Trypan Blue exclusion and the Cell Proliferation kit
(MTT, Roche Diagnostics Comp., Indianopolis, IN), fol-
lowing the manufacturer’s instructions. A 50% inhibition
of cell growth was taken as a comparative index of cyto-
toxicity (IC50). To verify the inhibitory effect of DTT on
C7a cytotoxic effect, cells were pre-incubated with 2
mM dithiothreitol (DTT, Sigma Aldrich, MO) for 10
minutes, and then with a high dose of C7a (10 μM) for
1 or 2 h. Alternatively, cells were incubated for 2 h with
DTT, carefully washed with serum-free medium and
then incubated with 1 μM C7a for 1 and 2 h. Viable
cells were counted by Trypan Blue exclusion, and each
IC50 value was calculated using at least 3 separate
experiments.
Isolation of rat liver mitochondria (RLM)
Mitochondria were isolated by conventional differential
centrifugation [17] from the liver of adult rats. Male
Wistar rats weighing approximately 180 g were sacri-
ficed by cervical dislocation and the liver was immedi-
ately removed and homogenized in 250 mM sucrose, 1
mM EGTA, and 10 mM HEPES-KOH buffer (pH 7.2) in
a Potter-Elvehjem homogenizer. Homogenates were cen-
trifuged at 770 g for 5 min and the resulting supernatant
was further centrifuged at 9800 g for 10 min. Pellets
were suspended in the same medium containing 0.3
mM EGTA and centrifuged at 4500 g for 15 min. The
final pellet was resuspended in 250 mM sucrose and 10
mM HEPES-KOH buffer (pH 7.2) to a final protein con-
centration of 80-100 mg/ml. All studies with mitochon-
dria were performed within 3 h and mitochondrial
protein content was determined by the Biuret reaction
[18].
Mitochondrial swelling
Rat liver mitochondria (0.25 mg protein/ml) were sus-
pended in a medium containing 125 mM sucrose, 65
mM KCl, 10 mM HEPES-KOH, pH 7.4, at 30°C plus 5
mM potassium succinate, 2.5 μM rotenone and 10 μM
CaCl2. Complex 7a was added 10 seconds after the start
of data recording. The mitochondrial swelling was esti-
mated from the decrease in the relative absorbance at
540 nm in a Hitachi U-2000 Spectrophotometer (Tokyo,
Japan).
Measurement of mitochondrial membrane potential (ΔΨ)
in isolated mitochondria
Mitochondrial ΔΨ was estimated under the same experi-
mental conditions of the swelling assay. Changes of 0.4
μM rhodamine 123 fluorescence were recorded on a
Hitachi F-2500 Spectrofluorometer (Tokyo, Japan) oper-
ating at 505/525 nm with a slit width of 5/5 nm, excita-
tion/emission, respectively. The results are expressed as
percentage of dissipation in relation to uncoupled mito-
chondria (carbonyl cyanide trifluoro-methoxyphenylhy-
drazone, FCCP, Sigma Chemical, MO, 1.0 μM).
Measurement of extracellular acidification rate
HCT-8, SiHa and SKmel25 human tumor cells (3 × 10
5)
were seeded on 3 μm pore transwells (Corning Costar),
and grown in complete culture medium containing 10%
FCS in 12-well culture plates for 12 h before the
Figure 1 Schematic representation of the cyclopalladated C7a
complex, [Pd2(S(-)C
2, N-dmpa)2(μ-dppe)Cl2].
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treated and untreated cells was determined using a
Cytosensor Microphysiometer (Molecular Devices, Grä-
felfing, Germany). Capsules containing the adherent
cells were transferred to sensor chambers and kept in a
low buffered RPMI containing 1% BSA at 37°C for 20
min, until extracellular acidification rate stabilization,
producing a basal line. The perfusion medium was then
pumped through each sensor chamber at 50 μl/min, and
pumping cycles consisted of a flow period of 90 sec, fol-
lowed by a flow-off period of 30 sec. During these peri-
ods, protons released from the cells accumulated in the
sensor chamber, and the slope of the H
+ profile was
quantified every 2 minutes. Cells were perfused with
low-buffered medium containing 1% BSA (control), 10
μMC 7 ao r2 0 0μM Cisplatin, both compounds diluted
in the same medium. Compounds were maintained until
the end of the experiment.
ΔΨm (mitochondrial transmembrane potential)
measurement in intact tumor cells
Mitochondrial membrane potential measurements were
carried out as described previously [19]. Briefly, 5 ×
10
4 B16F10-Nex2 cells were seeded on 25 mm
2 poly-
lysine (1 mg/ml) pre-treated coverslips. After cell
attachment, coverslips were placed in Leiden coverslip
chambers, and cells were incubated with 50 nM of
TMRE (tetramethylrhodamine ethyl ester, Molecular
Probes, OR, USA) for 15 minutes at room temperature.
The apparatus was transferred to a thermostatically
regulated microscope chamber (37°C, Harvard Instru-
ments, MA, USA) and 1 μM C7a, or alternatively 10
μMC 7 ai nt h ep r e s e n c eo f2m MD T T ,w a sa d d e d .
TMRE fluorescence (548 nm excitation and 585 nm
emission) was acquired immediately after C7a addition
at 1 frame/6 seconds using a TE300 Nikon inverted
microscope (Nikon Osaka, Japan) and a 16 bit cooled
CCD camera CoolSnap (Roper Sci, Princeton Instru-
ments, USA) controlled by imaging software (BioIP,
Wilmington, DA). Because of the high resolution, indi-
vidual mitochondria were localized, especially at the
borders of the cells, and the regions of interest (ROI)
were drawn surrounding each mitochondrion. For cali-
bration, at the end of each experiment (after 90-100
images captured) 5 μM FCCP (Sigma Chemical, MO,
USA), a protonophore uncoupler that collapses ΔΨm,
was added. Fluorescence intensity was measured in
arbitrary units. At least 100 mitochondria/coverslip
and nine coverslips/treatment were analyzed. In addi-
tion, cells showing depolarization (decrease), hyperpo-
larization (increase) or no change in the mitochondrial
fluorescence were visually counted. The assay was
done in triplicate, and at least 200 cells were counted
in each slide.
Bax translocation
B16F10-Nex2 cells (5 × 10
4)w e r es e e d e do n2 5m m
2
poly-lysine (1 mg/ml) pre-treated coverslips. After
attachment, cells were transfected with a GFP-Bax plas-
mid as described previously [20]. Briefly, 0.5 μg of GFP-
Bax plasmid and 4 μl of LipofectAmine (Life Technolo-
gies, Gaithersburg, MD, USA) were used per coverslip.
Cells were incubated for 5 h in the transfection mixture
at 37°C, placed in Leiden coverslip chambers and
adapted to the microscope, where the temperature of
the specimen was maintained at 35-37°C. The complex
C7a (1 μM) was then added and GFP-Bax translocation
from cytosol to intracellular compartments was observed
using an inverted confocal microscope LSM510 (Carl
Zeiss, Heidelberg, Germany) equipped with ArKr 488/
568, HeNe 543 lasers and 40 × Apochromat objective.
Alternatively, intracellular calcium was chelated with 20
μM 1,2-Bis(2-aminophenoxy)ethane-N,N,N’,N’-tetraace-
tic acid tetrakis (acetoxymethyl ester) (BAPTA-AM,
Sigma Chemical, MO, USA) for 20 minutes before C7a
addition. For mitochondrial colocalization of Bax, trans-
fected cells were loaded with 20 nM tetramethylrhoda-
mine ethyl ester perchlorate (TMRE) for 10 minutes
previously to the addition of C7a complex. Time course
analyses of treated cells were carried out at 30 min
intervals to monitor changes in GFP-Bax and TMRE
localization
Calcium measurements assay
B16F10-Nex2 cells (5 × 10
4)w e r es e e d e do n2 5m m
2
poly-lysine (1 mg/ml) pre-treated coverslips. After cell
attachment, coverslips were incubated with 2 μMF u r a -
2-AM (Molecular Probes, OR, USA) plus 20% Pluronic
F127 (Sigma Chemical, MO, USA) for 30 minutes at
room temperature. The coverslips were then washed
and placed in Leiden coverslip chambers, adapted to the
microscope, where the temperature of the specimen was
maintained in 35-37°C. Cytosolic concentration of cal-
cium on untreated cells was normalized to the zero
v a l u eo fF l u o r e s c e n c eR a t i o3 4 0 / 3 8 0n m .C o m p l e xC 7 a
(1 μM) was then added (Image number Zero) and
images were collected at 3 sec intervals by using a
TE300 Nikon inverted microscope (Nikon Osaka, Japan)
coupled to 16 bit cooled CCD camera CoolSnap (Roper
Sci, Princeton Instruments, USA) controlled by imaging
software (BioIP, Wilmington, DA). Fura-2, a ratiometric
calcium dye, was excited at 340 and 380 nm with emis-
sion acquired at 505 nm. Readings at 340 and 380 nm
were used to calculate fluorescence ratios, which repre-
sented the variations in cytosolic calcium under these
circumstances. Single cells were then analyzed using the
ROI tool, fluorescence intensities obtained were normal-
ized and plotted using the BioIP software and Kaleida
Graph Synergy software. The effect of C7a was
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cium, and the maximum effects evoked by C7a under
these conditions were plotted in a histogram. Seven
cells/coverslip from at least nine different experiments
were analyzed.
Quantification of cytosolic ATP
Cytosolic ATP concentration was measured using a bio-
luminescence assay kit (Adenosine 5’-triphosphate biolu-
minescent somatic cell assay kit, Sigma-Aldrich). Briefly,
2×1 0
4 plated cells were treated with 1 μMC 7 a( 1 0 0
μl) for 15, 30, 45 or 60 minutes. Cells (or medium, as
control) were lysed in 100 μl of ATP-releasing reagent
and 50 μl of this suspension was added to 50 μlo fA T P
assay mix solution into each well of white 96-well plates.
Light emission was measured at 570 nm in a Spectra-
MaxL luminometer (Molecular Devices, CA, USA). A
standard curve obtained with diluted ATP solutions was
used to calculate ATP concentrations in samples.
Identification of activated caspases
The ApoTarget™ Caspase Colorimetric Protease Assay
kit (Invitrogen, CA, USA) was used for measurement of
caspase-2, caspase-3, caspase-6, caspase-8 and caspase-9
activities in cell lysates. Briefly, B16F10-Nex2 cells (5 ×
10
6) were treated in vitro with 1 μM C7a for 5 minutes.
As a positive control, B16F10-Nex2 cells were exposed
to ultraviolet (UV) light for 7 minutes. Cell lysates were
obtained following manufacturer’s instructions and cas-
pase activity was measured at 400-405 nm as free p-
nitroaniline released from p-nitroaniline-labeled specific
substrates. Alternatively, caspase-3 activity was mea-
sured by flow citometry. B16F10-Nex2 cells (1 × 10
6)
were treated for 12 h with 1 μMC 7 ao r1 0μMA c t i n o -
mycin D, as a positive control. The cells were collected
and incubated with Anti-ACTIVE
® Caspase-3 policlonal
antibody (Promega, WI, USA) diluted 1:1000 in PBS/
BSA 1% for 1 h on ice and maintained in the dark. Sam-
ples were evaluated in a FACScalibur Flow Cytometer
(BD Biosciences, CA, USA), using CellQuest
® software.
Analysis of nuclear alterations
B16F10-Nex2 cells (5 × 10
4)w e r eg r o w nf o r1 2ho n
sterile 25 mm
2 coverslips in 6-well tissue culture plates.
Cells were treated with 1 μM C7a and coverslips col-
lected at different times were washed with PBS and
stained with Hoechst 33342 (Sigma-Aldrich, MO, USA)
for 15 minutes. Coverslips were inverted on slides and
analyzed in an Olympus BX61 microscope (magnifica-
tion 400 ×) at 360 nm. The images were acquired using
Cell^M Software. Nuclear alterations in at least 200
cells for each time point were visually observed and
counted, and the frequency of cells showing alterations
was calculated. The assay was repeated three times.
Morphological analyses
For analysis of morphological changes in tumor cells by
light microscopy, B16F10-Nex2 cells (1 × 10
4)w e r e
grown for 12 h on sterile 13 mm
2 coverslips inserted
into 12-well tissue culture plates (Corning Costar). Cells
were treated with 1 μM C7a and coverslips collected at
different times were washed in PBS, inverted on glass
slides and analyzed in an Olympus BX61 microscope
(magnification 1000 ×). The images were acquired using
Cell^M Software. For transmission electron microscopy
(TEM) analysis, B16F10-Nex2 cells (5 × 10
4)w e r e
grown for 12 h on sterile 13 mm
2 coverslips in 12-well
tissue culture plates. Cells were treated with 1 μMC 7 a
for 15 min and fixed in glutaraldehyde 2.5% in sodium
cacodylate buffer 0.1 M, pH 7.4. The post-fixation was
performed using 1% osmium tetroxide, 0.08% potassium
ferricyanide, 5 mM calcium chloride in the same buffer
for 60 minutes in the dark. Dehydration was made in
series of acetone and infiltration in polybed epoxy resin
(Polysciences, PA, USA). Ultrathin sections obtained by
ultramicrotomy were collected in grids (300 mesh) and
contrasted in uranyl acetate and lead citrate. The ultra-
structural analysis was done in a transmission electron
microscope Zeiss EM-900.
Treatment of Experimental Tumor Metastasis
C57Bl/6 mice were injected intravenously into the tail
vein with 5 × 10
5 B16F10-Nex2 viable cells in 100 μLo f
RPMI medium. Intraperitoneal injections of C7a (200
ng·kg
-1) or PBS (control group) started 24 h after tumor
inoculation, and treatment was repeated 3 times a week
for 13 days. Animals were killed by cervical dislocation
on day 15
th, lungs were collected and pulmonary
nodules were counted using an inverted microscope.
Statistical analysis
Statistical analysis was performed using Student’s t Test
from Microsoft Excel (Microsoft Office Software).
Values (p) equal to or less than 0.05 were considered
significant.
Results
C7a complex enters passively tumor cells in vitro and
affects cell morphology
Murine melanoma B16F10-Nex2 cells were incubated
with Complex C7a at 4°C or 37°C, and no difference in
the cytotoxicity of C7a at both temperatures was
observed (Additional file 1, Figure S1). This result sug-
gests that Complex C7a enters passively the tumor cells,
independently of a specific receptor.
The cell morphology of B16F10-Nex2 cells treated
with C7a was examined by light microscopy, and
changes occurred very early after treatment. After 5
minutes incubation with C7a, B16F10-Nex2 cells had
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ulation associated with nuclear condensation. Altera-
tions were time-dependent (Additional file 2, Figure S2).
Complex 7a has a direct effect on isolated mitochondria
The direct effects of Complex 7a on isolated rat liver
mitochondria were investigated. As observed in the Fig-
ure 2A, the addition of the palladacycle on mitochon-
drial suspension energized with potassium succinate
resulted in a concentration-dependent swelling. This
effect started at 250 nM and reached the maximal effect
at 2.5 μM concentration. Such swelling indicates the
occurrence of the inner mitochondrial membrane per-
meabilization associated with the disruption of ionic
homeostasis in mitochondria. In this way, it was also
observed the dissipation of the mitochondrial trans-
membrane potential induced by the addition of Com-
plex 7a to the mitochondrial suspension due to the
permeabilization promoted by the cyclopalladated com-
pound (Figure 2B).
Cyclopalladated C7a induces a collapse of the
mitochondrial membrane potential (ΔΨm) by interacting
with protein-thiol groups in intact tumor cells
B16F10-Nex2 cells were incubated with TMRE, a fluor-
escent probe used to measure ΔΨmv a r i a t i o n s .I nr e s t -
ing conditions, mitochondria appear as elongated
structures regularly distributed in the cell cytoplasm.
C7a-treated cells showed a rapid and strong decrease in
fluorescence intensity that was sustained until FCCP
was added. FCCP was used to promote the collapse of
ΔΨm (Figure 3A). The histogram in Figure 3B is repre-
sentative of the ΔΨm variations throughout the assay of
one single organelle from treated cells. As shown in
Table 1, the majority of mitochondria analyzed in C7a-
treated cells (88%) showed a decrease in TMRE fluores-
cence (depolarization), while the remaining showed an
increase (hyperpolarization) or no effect on TMRE
fluorescence after treatment with the cyclopalladated
compound.
Recently, Santana et al. [21] demonstrated that an
enantiomer of cyclopalladated C7a {Pd2 [R(+)C
2,N -
dmpa]2 (μ-dppe)Cl2} interacts with thiol groups of the
membrane proteins from rat liver isolated mitochondria,
promoting specific protein thiol cross-linkage, inducing
mitochondrial permeabilization and cytochrome c
release. This effect was abolished by preincubation of
isolated mitochondria with DTT, a thiol reducing agent.
To analyze whether C7a could induce the same effect
on intact tumor cells, B16F10-Nex2 cells were incubated
in vitro with C7a in the presence of DTT. The cytotoxic
effect of C7a on B16F10-Nex2 cells was significantly
inhibited by DTT, with more than 90% of treated cells
remaining viable after 1 h and 2 h incubation (Figure
3E). Corroborating this result, the rapid ΔΨm dissipa-
tion induced by C7a was completely inhibited by DTT
( F i g u r e3 C ,Da n dT a b l e1 ) .T od i s c a r dap o s s i b l e
quenching reaction between C7a complex and DTT
prior to cell interaction, since DTT has free SH groups
in its structure, B16F10-Nex2 cells were pretreated with
DTT for 2 h, carefully washed with serum-free medium
and then incubated with C7a. In this experimental set-
ting, DTT inhibited the cytotoxic effect of C7a as
observed previously (data not shown).
Bax-translocation to mitochondria induced by C7a
Bax is a pro-apoptotic member of Bcl-2 protein family
located predominantly in the cytosolic compartment,
and in monomeric form in healthy cells. After an apop-
totic stimulus, a significant fraction of Bax protein trans-
locates to the outer mitochondrial membrane [22] and
after insertion into mitochondria, Bax may form large
oligomers at the membrane.
To verify if C7a was capable of activating Bax indu-
cing protein translocation, B16F10-Nex2 cells were
A
Figure 2 Complex 7a-induced mitochondrial permeabilization
results in swelling and electrochemical gradient dissipation on
isolated rat liver mitochondria. (A) Mitochondrial swelling was
estimated by decrease of the relative absorbance recorded at 540
nm (rA540); (B) ΔΨ was measured by using 0.4 μM rhodamine 123
and mitochondria were energized by the addition of 5 mM
succinate (suc). The arrows indicate the addition of Complex 7a, the
numbers are the cyclopalladated compound concentrations at μM,
and the traces are representative of at least three experiments with
different mitochondrial preparations. C represents untreated
mitochondria (in dotted lines).
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Page 6 of 16transfected with a recombinant GFP-Bax plasmid and
treated with the complex. Figure 4A, B shows that C7a
evoked a punctuated pattern characterized by intense
dotted profile indicating that the compound induced
Bax-translocation to mitochondria, as observed by the
colocalization with TMRE (Figure 4D). Untreated cells
showed a diffuse pattern of GFP fluorescence character-
istic of soluble Bax in the cytosol.
Calcium contibutes to cell death caused by C7a
Calcium transients are important events for cell phy-
siology and the regulation of this signaling process
depends on a complex machinery, which maintains
cytosolic calcium at nanomolar levels in resting condi-
tions [23]. Increase in intracellular calcium
concentrations may trigger apoptotic pathways or even
amplify other apoptotic stimuli. C7a treatment of
B16F10-Nex2 cells induced a significant increase in
cytosolic calcium (Figure 5A), which may be released
mainly from intracellular organelles, such as mitochon-
dria and endoplasmic reticulum, since the effect was
present even when cells were incubated in a calcium-
free buffer (Figure 5B). In Figure 5C, the histogram
shows the maximum increase in Fura-2 ratio induced
by C7a in the presence or absence of calcium. In the
presence of a regular buffer (with calcium), the cytoso-
lic calcium response was even greater indicating that
the extracellular calcium may also participate in C7a-
induced calcium increase. Fluorescence intensities were
not changed and remained stable in the absence of
C7a (data not shown).
To corroborate the participation of Ca
+2 on the mito-
chondrial effect of C7a complex, B16F10-Nex2 murine
melanoma cells were pre-incubated for 20 minutes with
BAPTA-AM, an intracellular calcium chelator, before
C7a addition and in a Ca
+2-containing medium. It was
observed that Bax was unable to translocate to mito-
chondria in this condition, as evidenced by the mainte-
nance of the original diffuse pattern (Figure 4C).
Figure 3 Effect of C7a on mitochondrial membrane potential in intact cells, and inhibitory effect of DTT on C7a. (A1 and C1) Representative
image of ΔΨm in B16F10-Nex2 cells in resting conditions after incubation with TMRE. White squares represent one ROI, as described in Material and
Methods; (A2) Representative image of TMRE-incubated cells immediately after C7a addition; (A3) Representative image of TMRE/C7a-treated cells
immediately after FCCP addition. Scale bars, 20 μm. Images show one of 30 similar images that were acquired at 1 frame/6 seconds, 400 ×
magnification. (B and D) Representative traces of TMRE fluorescence over time in B16F10-Nex2 cells, arrows show the moment C7a or FCCP were
added to the cells. (C2) Representative image of TMRE-incubated tumor cells, pretreated with DTT and immediately after C7a addition. (C3)
Representative image of TMRE/C7a/DTT-treated tumor cells immediately after FCCP addition. Scale bars, 20 μm. Images were acquired as described in
(A). (E) Cytotoxic effect of C7a in the presence or absence of DTT. The percentage of viable cells related to untreated control is represented. *p < 0.05,
compared to untreated cells at the same time. Each experiment was performed at least 3 times.
Table 1 Frequency of B16F10-Nex2 cells showing
alterations in mitochondrial membrane potential after
C7a or C7a + DTT treatment.
C7a (%) C7a+ DTT (%)
Depolarization 88.0 ± 1.5 6.0 ± 0.6
Hyperpolarization 11.0 ± 2.5 9.0 ± 1.6
No change 1.0 ± 1.5 85.0 ± 2.0
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Page 7 of 16C7a treatment of intact tumor cells causes mitochondrial
swelling and decreased ATP production
Our results suggest that the mitochondrial membrane of
intact tumor cells was strongly affected by C7a treat-
ment, by opening the mitochondrial permeability transi-
tion pore complex (PTPC) in association with Bax
polymerization at the membrane. The pore-forming
effect associated with the rapid collapse of the ΔΨm
caused by cyclopalladated C7a, may induce several other
modifications in mitochondria, such as uncoupling of
ATP synthesis from oxidative phosphorylation and
mitochondrial swelling [24].
Swelling of mitochondria could be observed in trans-
mission microscopy images of treated cells. Untreated
Figure 4 Bax translocation to mitochondria in GFP-Bax-transfected B16F10-Nex2 cells after treatment with C7a is dependent on Ca
2+.
(A) Representative images of untreated cells and after 3 h treatment; (B) Representative images after selected time points of an individual
tumor cell; (C) The same assay performed in (B) with transfected cells preincubated with 20 μM of BAPTA before C7a addition; (D)
Representative images show Bax-transfected C7a-treated cells after 2 h (1), co-stained with TMRE (2) and overlayed image (3). Scale bars, 20 μm
in (A), 40 μm in (B) an (C) and 30 μm in (D). Images are representative of at least three individual experiments.
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Page 8 of 16B16F10-Nex2 cells showed intact mitochondria with
elongated shape and preserved lamellar cristae (Figure
6A). In contrast, C7a-treated cells showed swollen mito-
chondria with irregular shape, undefined cristae and
ruptured membranes (Figures 6B, C).
Mitochondria swelling and collapse of ΔΨm results in
the arrest of ATP synthesis by these organelles, and in
fact, treatment with C7a did affect ATP synthesis in
B16F10-Nex2 cells. More than 30 minutes incubation
with the compound was, however, necessary to reduce
50% ATP concentration. After 1 h, 15% of the initial
concentration of ATP was still detected (Figure 6D).
C7a treatment releases caspase-activators and
endonucleases from mitochondria in intact tumor cells
Alterations in mitochondrial permeability may release
numerous proteins that are normally confined within
the mitochondrial intermembrane space where they
exert vital functions. Among them are caspase activators
and endonucleases [25].
In B16F10-Nex2 cells all caspases tested were acti-
vated by C7a, including the effector caspases 3 and 6,
responsible for the final events of apoptosis (Figure 7A,
B). As positive control, exposure to ultraviolet (UV)
radiation also induced activation of caspases. Interest-
ingly, the levels of effector caspases 2, 3 and 6 activation
were higher in cyclopalladated C7a-treated cells com-
pared to UV treatment (Figure 7A).
C7a treatment also caused release of endonucleases
from mitochondria, with the expected nuclear altera-
tions and DNA degradation. Significant nuclear altera-
tions were observed in C7a-treated cells, as observed
after Hoechst 33342 staining. While no significant chro-
matin condensation was observed in untreated cells, pic-
notic nuclei were observed in 85% cells after 25 minutes
incubation with C7a, and this effect was time-dependent
(Figure 7Cand Table 2).
Cyclopalladated C7a was effective in a pre-clinical model
of metastatic melanoma
To analyze the effect of C7a on metastatic melanoma
growth, C57Bl/6 mice were injected endovenously with
tumor cells and intraperitoneally treated with C7a for
13 days. The number of lung nodules was counted after
15 days. The treatment protocol significantly reduced
the number of lung nodules (Figure 8).
Cyclopalladated C7a was cytotoxic in vitro against human
tumor cells and affected the respiratory metabolism
The cytotoxic effect of C7a was tested in vitro against
several human tumor cell lines, and viable cells were
determined by two different methods (Table 3). The
effect was dose-dependent (not shown), and the IC50
values for the majority of human tumor cell lines tested
were below 400 nM. Me91 and SKMel25 were the most
sensitive cell lines, both isolated from human melano-
mas. The IC50 for B16F10-Nex2 murine cell line was
420 nM, superior to the values obtained for sensitive
human tumor cell lines. Human leukemia (HL-60) and
glioblastoma (U-97) cell lines showed the highest IC50
values, 1.0 and 3.5 μM, respectively. Cisplatin, a stan-
dard chemotherapeutic compound, was cytotoxic in
some human cell lines, with IC50 values ranging from 66
to 176 μM. Some human cell lines tested were signifi-
cantly resistant to cisplatin, with IC50 values superior to
200 μM. Remarkably, C7a compound was cytotoxic in
these cisplatin-resistant cells (LS-180, HCT-8, ZR753A,
SiHa and SKMel25).
The C7a complex induced an abrupt inhibition of the
respiratory metabolism in B16F10-Nex2 cells [14], and
this result suggested that mitochondria were involved in
the cell death process, which was confirmed by the
experiments described here. The same parameter was
therefore analyzed in some C7a-sensitive human tumor
cell lines, by measuring the effect of the cyclopalladated
compound on the extracellular acidification rates using
the Cytosensor microphysiometer. While untreated cells
maintained baseline values of extracellular H
+
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Figure 5 Increase in cytosolic calcium induced by C7a. Calcium
concentration was evaluated in B16F10-Nex2 cells incubated with
regular or calcium-free buffer. (A) and (B) Representative
fluorescence ratio (340/380) traces of single cells are shown after
C7a (1 μM) addition at Image Zero in the presence (A) or absence
of calcium in the buffer (B). (C) Histogram shows the media ±
standard deviation of the fluorescence ratio at 340/380 in all cells
analyzed. Normalized fluorescence value was determined before
C7a addition and data were expressed as percentage in relation to
the baseline. *, p < 0.05. The results are representative of 3
independent experiments.
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Page 9 of 16throughout the experiment, C7a-treated human tumor
cells showed an abrupt decay of extracellular acidifica-
tion values, similarly to those observed in murine mela-
noma cells (Figure 9). The respiratory metabolism of
human tumor cells was slightly affected by cisplatin.
Discussion
Elucidating the mechanism of action of a cytotoxic com-
pound can be a challenging task. For example, 40 years
have passed since the discovery of the anticancer activity
of cisplatin, and the mechanism of action of this com-
pound is still unclear. It is now believed that cisplatin
enters the cell by passive diffusion and by copper trans-
porter hCtr1 (human Cu transporter 1) pathways [26].
Once inside the cytoplasm, the low chloride concentra-
tion causes cisplatin to undergo aquation and hydrolysis
reactions generating various positively charged platinum
species. The aquated platinum complexes are believed
to bind to nuclear DNA or to other weak nucleophiles
such as carbonate and phosphates, but it has been
demonstrated that only a small fraction of intracellular
cisplatin binds to nuclear DNA triggering the events
that will lead to cell death. On the other hand, cisplatin
and the aquated complexes react readily with methio-
nine, metallothioneins and glutathione (GSH), and this
is believed to be the cause of the high rate of resistance
induced by this compound [reviewed in [27]]. The
mechanism or mechanisms by which nuclear cisplatin/
DNA adducts generate the cytoplasmic events leading to
apoptosis have not been defined yet [28]. However,
recent reports demonstrate that cisplatin binding to
nuclear DNA is not necessary for induction of apoptosis,
and that mitochondria may be the main target on tumor
cells, although the precise target in these organelles is
not known [reviewed in [28]].
Mitochondria in tumor cells are structurally and func-
tionally different from the organelles in non-transformed
cells, and recently they are emerging as a selective target
for tumor chemotherapy [29].
Santana et al. [21] showed that a cyclopalladated com-
pound targets mitochondria. Four cyclopalladated com-
pounds derived from dmpa complexed to dppe were
tested against hepatoma cells and shown to be cytotoxic
in vitro. The most effective compound was the R(+)
enantiomer of C7a complex, {Pd2 [R(+)C
2,N - d m p a ] 2 (μ-
dppe)Cl2}. This R(+) enantiomer of C7a was further
tested in isolated rat liver mitochondria, causing mito-
chondrial permeabilization, as indicated by Ca
+2-a n d
ROS-independent mitochondrial swelling, and release of
cytochrome c. Associated with the mitochondrial
Figure 6 Transmission electron microscopy and intracellular ATP concentration after C7a treatment. (A) Untreated control cells; (B and
C) C7a treated cells. N, nucleus; M, mitochondria; PM, plasma membrane. Scale bars, 0.5 μm; (D) B16F10-Nex2 cells were treated with C7a and
the ATP levels were evaluated at different time points, as described in Materials and Methods. *, p < 0.05 and **, p < 0.01, compared to cells at
time zero. Results are representative of 3 independent experiments.
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Page 10 of 16Figure 7 Caspase activation and nuclear alterations after treatment with C7a. (A) Activation of caspases after C7a treatment measured by
a colorimetric assay. Ctrl, untreated tumor cells; UV, positive control, cells submitted to UV irradiation. (B) Percentage of activated caspase-3-
positive cells in flow citometry after Actinomycin D or C7a treatment. Control, untreated tumor cells incubated with anti-active caspase 3
antibody. (C) Representative images of C7a-treated B16F10-Nex2 cells after nuclear staining with Hoescht 33342. Arrows represent nuclear
alterations. Magnification, 400 ×, and scale bars, 20 μm. Results are representative of at least 2 independent experiments.
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Page 11 of 16swelling, dissipation of mitochondrial transmembrane
potential, uncoupling of the oxidative phosphorylation,
and mitochondrial calcium release were observed. These
effects were completely inhibited by dithiothreitol
(DTT). Importantly, it was observed a decrease in the
content of reduced thiol groups in the mitochondrial
membrane proteins of treated cells, as well as the pre-
sence of membrane protein aggregates without lipid and
GSH oxidation. This effect was related to the formation
of disulfide bonds between critical thiol groups in mito-
chondrial membrane proteins, suggesting that
cyclopalladates could act as thiol reagents, catalysing
specific protein thiol cross-linkage and initiating mito-
chondrial effects. Interestingly, cyclopalladated-induced
mitochondrial permeabilization depended on the entire
structure of the compound and not on the palladium
atom alone, since PdCl2 was not able to promote per-
meabilization. It is noteworthy that the R(+) enantiomer
of C7a, although cytotoxic in vitro, was not effective in
vivo against murine melanoma B16F10-Nex2, possibly
because of the presence of a S(-) anomeric carbon on
C7a that stabilizes the molecule by an intramolecular
hydrogen bridge formation [14,21]. To compare with
the R(+) enantiomer, the mechanism of action of the
cyclopalladate complex C7a, that was otherwise effective
in vivo, was investigated.
As observed for cisplatin [30,31], we found little differ-
ence in the cytotoxicity of C7a in murine melanoma
B16F10-Nex2 cells at 4°C or 37°C, suggesting a passive
entry of the compound in tumor cells.
Similarly to the R(+) enantiomer, we show here that
the C7a complex induced swelling of rat isolated mito-
chondria and dissipation of the mitochondrial trans-
membrane potential, associated with inner
mitochondrial membrane permeabilization.
The effect of C7a on intact B16F10-Nex2 cells was
completely inhibited by DTT, as observed for the R(+)
enantiomer on isolated mitochondria. This result sug-
gests that C7a may also induce mitochondrial permeabi-
lization by catalyzing the cross-linkage of vicinal thiol
Table 2 Frequency of cells showing nuclear alterations
after C7a treatment.
Time (min) Cells with nuclear alterations (%)
0 6.5 ± 0.4
5 12.5 ± 1.1
10 41 ± 1.5
25 85 ± 0.9
Figure 8 Antimetastatic activity of C7a. C57Bl/6 mice injected
endovenously with B16F10-Nex2 cells were treated i.p. with C7a. (A)
Number of pulmonary nodules 15 days after tumor inoculation,
each symbol represents one individual animal. Horizontal lines
represent the average and standard deviation; (B) Representative
images of lungs from treated (C7a) and untreated (Control)
animals. * p < 0.05. Results are representative of 3 independent
experiments.
Table 3 Comparison of IC50 values obtained for C7a and
cisplatin
IC50
Complex 7a (μM)
IC50
Cisplatin (μM)
Murine Melanoma
B16F10-Nex2
Human tumor lineages
0.42 ± 0.06 176 ± 15
Colon Cancer
LS-180 0.26 ± 0.07 >200
HCT-8 0.34 ± 0.05 >200
Breast Cancer
SKBr-3 0.26 ± 0.04 66 ± 7
ZR753A 0.34 ± 0.02 >200
Uterine Cervix Cancer
HeLa 0.30 ± 0.03 68 ± 4
CasKi 0.24 ± 0.01 140 ± 8
SiHa 0.19 ± 0.02 >200
Melanoma
Me91 0.14 ± 0.03 156 ± 8
SK-Mel 25 0.15 ± 0.01 >200
Leukemia
HL-60 1.0 ± 0.1 70 ± 5
Glioblastoma
U-87 3.5 ± 0.2 150 ± 20
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Page 12 of 16groups present in the mitochondrial membrane proteins
with the formation of disulfide bonds.
The cross-linkage of thiol groups in mitochondrial
membrane proteins was associated to the mitochondrial
permeability transition pore complex (PTPC) formation
and opening [32-34]. Many modulators of PTPC open-
ing are known, however, the biochemical nature of the
proteins assembled to form the PTPC is not completely
elucidated. A proposed model suggests that apposition
of VDAC (voltage-dependent anion channel) and ANT
(adenine nucleotide translocator) at contact sites
between the mitochondrial outer and inner membranes
together with matrix CypD (cyclophilin D) could be
involved [35,36]. By using modulators of the PTPC for-
mation, it was demonstrated that the R(+) enantiomer
of C7a induced a pore with heterogenous composition,
formed by ANT in higher concentration than with
CypD molecules [21].
The oxidation of thiol groups in mitochondrial mem-
brane proteins was a direct effect of the R(+) enantiomer
of C7a, since generation of free radicals was not
observed. Interestingly, the relative lipophilicity of the
enantiomeric R(+) complex allows the preferential parti-
tioning of the cyclopalladated compound into biological
membranes and restricts its effects on critical thiol
groups of membrane proteins, as suggested by the
absence of oxidation of membrane lipids and GSH in
isolated rat mitochondria incubated with the compound
[14]. It remains to be determined whether or not GSH
could act as a detoxifying agent for C7a in intact tumor
cells.
The C7a complex caused mitochondrial swelling in
intact tumor cells, as observed in transmission electron
microscopy (TEM) images. Treatment of Jurkat cells
with cisplatin also induced similar morphological altera-
tions in mitochondria [37].
Marzo et al.[ 3 8 , 3 9 ]h a v es h o w nt h a tp r o -a n da n t i -
apoptotic members of the Bcl-2 protein family may
interact with the PTPC complex, suggesting that both
effectors are not completely independent from each
other, leading to mitochondrial membrane permeabiliza-
tion. The insertion of Bax into mitochondrial membrane
causes the release of cytochrome c and dissipation of
mitochondrial membrane potential (ΔΨm). Citochrome
c can interact with Apaf-1, and this complex in the pre-
sence of ATP, activates effector caspases and nucleases
leading to the proteolysis of the cell and nuclear frag-
mentation, while the loss of ΔΨm corresponds to arrest
in cellular energy production [reviewed in [40,41]]. The
present results demonstrate that C7a induces the trans-
location of recombinant GFP-Bax from cytosol to mito-
chondria, suggesting that mitochondrial
permeabilization caused by the cyclopalladated complex
is associated with PTPC formation and Bax transloca-
tion to the mitochondrial membrane.
The mitochondrial membrane potential (ΔΨm) is a
hallmark of the apoptotic cell death. During apoptosis,
nuclear disintegration can be preceded by loss or entire
dissipation of the ΔΨm [42], which may occur shortly
before or simultaneously with Bax translocation to mito-
chondria membranes [20,24,43]. The mitochondrial per-
meabilization induced by C7a caused dissipation of
ΔΨm in most of the tumor cell mitochondria, and this
effect was completely abolished by previous incubation
with DTT. In addition, it was also observed the inhibi-
tion of respiratory activity and decrease in energy pro-
duction, as inferred from the decrease in the
extracellular acidification [14] and ATP, respectively.
We also tested caspase activation in C7a-treated
tumor cells. B16F10-Nex2 cells were incubated with C7a
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Figure 9 Acidification response of human cancer cells to C7a.
Cells were placed on the Cytosensor System and allowed to
equilibrate in low buffered RPMI containing 1% BSA to normalize
the acidification rate in 100% (Buffer). C7a and Cisplatin were
diluted in the same medium, added at zero time and maintained
during the whole assay. Cells were monitored every 2 min. (A) HCT-
8 cells; (B) SiHa cells; (C) SKmel25 cells. Results are representative of
2 independent experiments.
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Page 13 of 16and caspase activation was measured in cell lysates
showing a strong activation of caspases 2, 3 and 6. Cas-
pases 3 and 6 were more activated in C7a- than in UV-
treated cells, a classical apoptotic stimulus. Activation of
caspase 3 was also observed by flow cytometry in C7a-
treated tumor cells. Caspase activation and chromatin
condensation presently shown and DNA degradation
detected previously [14] indicated that C7a induced
apoptotic cell death in tumor cells. The increase of cas-
pase-8 activation suggests that C7a treatment of tumor
cells may also affect a receptor-mediated reaction in
addition to the intrinsic pathway of cell apoptosis.
The C7a complex induced an increase in cytoplasmic
Ca
2+ probably also as an effect of Bax which modulates
Ca
2+ concentration in mitochon d r i aa n dt h ee n d o p l a s -
mic reticulum [44,45]. The involvement of Ca
+2 in the
apoptotic cell death induced by C7a compound was cor-
roborated by the inhibition of GFP-Bax translocation to
mitochondria when cells were pre-incubated for 20 min-
utes with BAPTA-AM, an intracellular calcium chelator,
before C7a addition.
Mitochondrial dysfunction has been implicated in
apoptosis and necrosis. Necrosis has been regarded until
recently as a passive and unregulated form of cell death,
however, it is now recognized that, except under
extreme conditions, this type of cell death is a well-
regulated process and may be called necroptosis [46,47].
The protein kinase RIP1, associated with the necrotic
cell death, can directly or indirectly induce mitochon-
drial permeability. Mitochondrial collapse activates var-
ious proteases (e.g., calpains, cathepsins) and
phospholipases, and eventually leads to plasma mem-
brane disruption, a hallmark of necrotic cell death [48].
T r e a t m e n tw i t hC 7 ad i dn o ti n d u c ep l a s m am e m b r a n e
disruption, as observed in light microscopy (Additional
file 2, Figure S2). In addition, incubation of tumor cells
with necrostatin, an inhibitor of RIP1 kinase [49], did
not affect the cytotoxic effect of C7a (data not shown).
In a preclinical model of primary melanoma, C7a sig-
nificantly delayed the subcutaneous murine melanoma
B16F10-Nex2 development, prolonging mice survival
[14]. In the present work, we demonstrated that C7a
significantly reduced the number of lung nodules in
endovenously-injected B16F10-Nex2 mice, suggesting
that the cyclopalladated compound is effective also in
controlling metastatic tumors. As demonstrated by
Hebeler-Barbosa et al. [15], the C7a complex may be
successfully used as an adjuvant in biochemotherapeutic
protocols against murine melanoma.
The antitumor effect of C7a was also tested against
human tumor cells, comparatively with cisplatin, the
standard metallic complex used in chemotherapy. The
IC50 values for the cyclopalladated compound, deter-
mined by 2 different methods, were 200 to 1.300 times
lower than the cisplatin IC50 values for the same tumor
cell line. In fact, even high doses (50 μM) of C7a were
not cytotoxic to murine macrophages or human ery-
throcytes in vitro (data not shown). These in vitro toxi-
city results agree with in vivo assays, in which mice
were treated with increasing doses of C7a for several
weeks with no toxicity been observed in vital tissues
[14]. As with murine melanoma, the C7a complex also
affects the respiratory metabolism of human tumor cells,
inhibiting the generation of protons in the respiratory
chain, thus suggesting that the cyclopalladated com-
pound may cause cell death by the same mechanism.
Conclusions
Our results suggest that the C7a complex enters tumor
cells passively, although it is not excluded the lateral
interaction with a cell ligand. It induces the intrinsic
apoptotic pathway, as demonstrated by the strong effect
on mitochondria. C7a interacts with protein thiol groups
in the mitochondrial membrane, induces Bax transloca-
tion to mitochondria, causes dissipation of ΔΨm, arrest
of ATP production, inhibition of respiratory activity,
cytosolic calcium increase and caspase/endonuclease
activation.
The C7a complex was cytotoxic in murine and human
tumor cells, including cisplatin-resistant lineages. In a
preclinical model of melanoma, C7a was effective
against primary and metastatic tumors, with low toxi-
city. The cyclopalladated C7a is therefore a promising
tumor chemotherapeutic agent, to be used alone or in a
combination therapy.
Additional material
Additional file 1: Figure S1; Temperature does not affect C7a effect.
B16F10-Nex2 cells, 5 × 10
3 plated on 96-well plates, were treated with 1
μM C7a. The cells were incubated for 6 h at 37°C or 4°C, and viable cells
were counted by Trypan blue exclusion. Incubation for 3 and 12 h
showed the same result (not shown).
Additional file 2: Figure S2; Morphological alterations after C7a
treatment. B16F10-Nex2 cells (5 × 10
3) were plated on 96-well plate and
treated with 1 μM C7a. Alterations in cell morphology were observed
after 5 (B),1 0(C) and 25 (D) minutes. (A) Untreated tumor cells. Images
were acquired in different areas of the cell culture. Magnification, 400 ×.
Scale bars, 20 μm.
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